Retatrutide is Eli Lilly's GLP-1/GIP/glucagon triple agonist, now the most efficacious obesity peptide ever read out in Phase 3. Phase 2 work showed mean weight loss above 24% at 48 weeks plus an 86% reduction in liver fat at 48 weeks, ahead of every approved drug.
TRIUMPH-1 topline released May 21, 2026 is the registrational readout that anchors the planned NDA. In 2,339 adults with obesity or overweight and at least one weight-related comorbidity without diabetes, retatrutide produced 28.3% mean weight loss at 12 mg, 25.9% at 9 mg, and 19.0% at 4 mg over 80 weeks versus 2.2% on placebo. 45.3% of participants on 12 mg reached ≥30% weight loss — bariatric-surgery territory. A 104-week extension in the BMI ≥35 subgroup pushed mean weight loss to 30.3% (85.0 lbs). Transient ALT elevations that surfaced in TRIUMPH-4 reappeared and normalized by week 24, consistent with hepatic triglyceride mobilization. Discontinuation rates ran 4.1%, 6.9%, and 11.3% across 4, 9, and 12 mg arms versus 4.9% placebo. TRIUMPH-4 in obesity with knee osteoarthritis posted 28.7% mean weight loss at 68 weeks plus 75.8% reduction in WOMAC pain. TRANSCEND T2D1 in type-2 diabetes reported A1c down 1.7 to 2.0 percentage points and 25 to 37 lb mean weight loss versus placebo. TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (obesity + established cardiovascular disease) read out later in 2026. The 10,000-patient TRIUMPH-OUTCOMES cardiovascular trial reads out 2027. Full TRIUMPH-1 data lands at ADA 2026 (June 5-8, New Orleans).
Retatrutide has also leaked into the unregulated research-peptide channel; the April 2026 Utah federal indictment of an osteopathic physician for selling 200+ patients misbranded Chinese peptides named retatrutide alongside semaglutide, tirzepatide, and BPC-157. The access fight took a sharper political turn on June 23, 2026 when STAT News disclosed that the FDA and Lilly granted a mystery 79-year-old patient compassionate-use access to retatrutide on the application of NIH senior clinician Dr. Ranganath Muniyappa, citing refractory obesity plus OSA plus pulmonary hypertension; outside experts told STAT the diagnoses don't clearly meet the compassionate-use threshold and the White House had to publicly deny that President Trump (who turned 80 on June 14) applied. The political escalation continued through June 24-25: White House senior deputy press secretary Kush Desai attacked STAT reporter Lizzy Lawrence as 'an unserious gossip columnist' (June 23-24), Rep. Ted Lieu (D-CA) suggested Trump canceled the 21st Century ROAD to Housing bill signing because he is receiving an experimental drug for terminal illness (June 24, prompting White House Communications Director Steven Cheung to call Lieu a 'dumba--'), and Senator Maggie Hassan (D-NH) sent a formal letter to HHS Secretary RFK Jr. on June 25 demanding answers and characterizing the use as 'a highly anticipated medication for obesity to a single VIP individual for free.' Lilly issued its first public statement on June 25: 'We make these decisions following all applicable regulations.' Stories here cover the trial readouts, mechanism work, the access-equity debate, the political fallout, and the gray-market enforcement track.
Eli Lilly's TRIUMPH program for retatrutide — a triple GIP/GLP-1/glucagon receptor agonist — has TRIUMPH-1 (general obesity without T2D, 80 weeks, 2,007 participants) and TRIUMPH-2 (obesity + T2D) reading out in Q2-Q3 2026. Both are pivotal for the planned NDA filing. The earlier TRIUMPH-4 readout in December 2025 delivered 28.7% mean weight loss at 68 weeks on 12 mg dosing with 75% knee osteoarthritis pain reduction. The full TRIUMPH program runs eight pivotal trials with >5,800 participants total: obesity, T2D, OSA, MASLD, knee OA, cardiovascular outcomes (TRIUMPH-OUTCOMES, ~10,000 patients reading out 2027), and dose-extension studies. A new safety signal noted in Phase 2 — a small uptick in mild-to-moderate hepatic enzyme elevations on 12 mg dosing — will be monitored carefully in Phase 3 readouts. Lilly's $4.5B Lebanon Indiana investment (announced May 6) targets retatrutide manufacturing capacity ahead of the 2027 approval window.
The American Diabetes Association 2026 Scientific Sessions opens in New Orleans on June 5 — three weeks out from today's Sunday digest. The peptide-relevant slate includes multiple Eli Lilly retatrutide TRIUMPH program presentations (some of the seven 2026 readouts expected to land at ADA), the Lilly + Indiana Biosciences Research Institute quintuple agonist (GLP-1/GIP/glucagon/amylin/calcitonin) animal-data poster on May 29, AstraZeneca's full Phase 2b VISTA and SOLSTICE data for eleglipron (formerly elecoglipron/AZD5004/ECC5004) after the April 29 topline, Innovent Biologics' mazdutide multi-program presentations (GLORY-2 18.55% weight loss, DREAMS-3 head-to-head vs semaglutide), Boehringer Ingelheim survodutide SYNCHRONIZE-1 full Phase 3 data, and Pfizer berobenatide (MET-097i) VESPER program updates. ADA combined with the May 21 ASCO abstract drop set up a heavy June peptide news cycle.
Eli Lilly on May 6 cut the ribbon on Lilly Lebanon Advanced Therapies — the company's first dedicated genetic medicine manufacturing facility — and committed an additional $4.5B across two more LEAP Research and Innovation District sites in Lebanon, Indiana. The new investment supports planned production of Foundayo (orforglipron), Lilly's only FDA-approved GLP-1 pill that does not require fasting or water restrictions, and retatrutide, the triple GLP-1/GIP/glucagon agonist in seven Phase 3 trials. Total Indiana capital commitments since 2020 now exceed $21B, with the LEAP District alone totaling $18B since 2022 — the largest capital project in Indiana history. The buildout will add more than 1,000 jobs by 2027 and gives Lilly a domestic Foundayo + retatrutide supply chain independent of peptide-CDMO bottlenecks.
Eli Lilly stock has gained roughly 11% over the past week, recovering from the May 4 Foundayo hepatic-failure FAERS report-driven 3% premarket dip and consolidating gains from the April 30 Q1 beat. Per the May 6 analyst consensus across 19 covering firms, LLY now carries an average 12-month price target of $1,228 — implying 24.15% upside from current $966 — with a Buy consensus rating. The recovery framework: tirzepatide volume (+125% global Q1 growth) anchors the floor, retatrutide TRIUMPH program (seven Phase 3 readouts due in 2026) anchors the upside, the small-molecule manufacturing economics of Foundayo offset peptide CDMO bottlenecks, and Pfizer's MariTide/MET-097i and Novo's CagriSema higher-dose program don't read out until 2027.
Eli Lilly's retatrutide MASLD Phase 3 trial (NCT06859268) is enrolling, building on Phase 2 data that reported up to 86% liver-fat reduction at 48 weeks with 93% of 12 mg patients reaching normal liver fat. The MASLD trial will measure histological resolution of steatohepatitis without worsening fibrosis — the endpoint that drives FDA approval in the indication. The trial sits within the broader TRIUMPH program of seven Phase 3 retatrutide readouts due in 2026, after TRIUMPH-4 (28.7% mean weight loss with knee-osteoarthritis pain reduction) and TRANSCEND T2D1 (A1c down 1.7–2.0 pts in T2D). MASLD remains a regulatory test for incretins after Boehringer's survodutide LIVERAGE Phase 3 program.
On the April 30 Q1 2026 call, Eli Lilly disclosed positive topline results from TRANSCEND T2D1, the first Phase 3 trial of retatrutide (triple GLP-1/GIP/glucagon agonist) in adults with type 2 diabetes. Compared with placebo, retatrutide lowered A1c by an average of 1.7 to 2.0 percentage points across doses and produced mean weight loss of 11.1 to 16.6 kilograms (25 to 37 pounds). The data complement the previously reported TRIUMPH-4 obesity-with-knee-osteoarthritis results (28.7% weight loss, 75.8% pain reduction). TRIUMPH-1, an 80-week obesity study, is the next retatrutide readout expected, with seven additional Phase 3 readouts still to come in 2026 ahead of a planned regulatory submission late 2026 or 2027.
Motley Fool analysis argues that retatrutide — Lilly's triple GLP-1/GIP/glucagon agonist showing up to 28.7% weight loss in Phase 3 TRIUMPH-4 — is the one thing that could firmly cement Lilly's dominance in the obesity drug market. With seven additional Phase 3 readouts expected in 2026 and a projected 2028 launch, retatrutide positions Lilly to extend its lead over Novo Nordisk.
Australia's Therapeutic Goods Administration warned of rising imports of unapproved peptide products promoted on social media, citing risks including severe allergic reactions, systemic inflammatory response, infection, and organ damage. Named products include BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295 — often supplied as injectables.
Eli Lilly's triple-agonist retatrutide met all primary and key secondary endpoints in Phase III TRIUMPH-4. The 9mg and 12mg doses achieved significant weight loss and knee pain reduction at 68 weeks in patients with obesity and osteoarthritis. Seven more Phase III readouts expected in 2026.
Clarivate projects orforglipron and retatrutide as the defining GLP-1 drugs of the next decade. Retatrutide is projected for 2028 launch after seven additional Phase III readouts expected this year.
Health Canada issued a public advisory warning against unauthorized injectable peptide drugs sold online for weight loss, anti-aging, and bodybuilding. Seized products include BPC-157, CJC-1295, retatrutide, and others, with cited risks of liver/kidney damage, blood clots, and cancerous tumours.
The FLOW trial showed semaglutide reduced major kidney events by 24%, and retatrutide demonstrated up to 28.7% weight loss in TRIUMPH-4. The full pipeline including CagriSema, MariTide, and survodutide was presented.
Retatrutide met its primary endpoint of superior A1C reduction and all key secondary endpoints at 40 weeks compared with placebo in type 2 diabetes patients, also demonstrating significant weight loss.
TikTok users on retatrutide report emotional blunting. Neuroscientist Paul Kenny of Mount Sinai says researchers are investigating whether GLP-1 drugs act as general reward dampeners affecting the brain's mesolimbic system.
Deep dive into the retatrutide hype cycle triggered by Andrew Huberman's endorsement and looksmaxxing influencers. Frames the triple-agonist as potentially more consequential than Ozempic.
Psychiatric Times provides educational review of the incretin system covering the shift toward oral nonpeptide small-molecule GLP-1 RAs and triple agonists expected within 1-2 years.
Eli Lilly's triple agonist (GIP/GLP-1/glucagon) retatrutide met its primary A1C reduction endpoint and all key secondary endpoints at 40 weeks in the TRANSCEND-T2D-1 trial.
Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist retatrutide demonstrated up to 28.7% weight loss along with significant knee pain reductions in obesity patients with osteoarthritis. Seven additional Phase 3 trials expected to report throughout 2026.